`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`·
`
`·1· · · · · · IN THE UNITED STATES DISTRICT COURT
`· · · · · · · · ·FOR THE DISTRICT OF DELAWARE
`·2· ·- - - - - - - - - - - - - - -x
`· · ·PFIZER INC. and UCB PHARMA· ·:
`·3· ·GMBH· · · · · · · · · · · · ·: C. A. No.
`· · · · · · · · · · · · · · · · · : 1:15-cv-000079(GMS)
`·4· · · · · · · · Plaintiffs,· · ·: Consolidated
`· · ·v.· · · · · · · · · · · · · ·:
`·5· · · · · · · · · · · · · · · · :
`· · ·MYLAN PHARMACEUTICALS INC., :
`·6· · · · · · · · · · · · · · · · :
`· · · · · · · · · Defendant.· · · :
`·7· ·- - - - - - - - - - - - - - -x
`
`·8
`
`·9· · · · · · · · · · ***CONFIDENTIAL***
`
`10
`
`11· · · · · · ·Oral deposition of LEONARD J. CHYALL,
`
`12· ·Ph.D. taken pursuant to notice, held on Tuesday,
`
`13· ·August 23, 2016, at the office of Kilpatrick
`
`14· ·Townsend & Stockton, 1114 Avenue of the Americas,
`
`15· ·New York, New York, commencing at 9:01 a.m. before
`
`16· ·Jamie I. Moskowitz, RPR, CRR, a Registered
`
`17· ·Professional Reporter and Notary Public.
`
`18· · · · · · · · · · · ·*· ·*· ·*
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 1
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 2
`
`·1· ·A P P E A R A N C E S:
`
`·2· ·KILPATRICK TOWNSEND & STOCKTON LLP
`· · ·BY:· D. CLAY HOLLOWAY, ESQUIRE
`·3· ·1100 Peachtree Street Northeast, Suite 2800
`· · ·Atlanta, Georgia· 30309
`·4· ·404.815.6500
`· · ·cholloway@kilpatricktownsend.com
`·5· ·Counsel for the Plaintiff
`
`·6
`
`·7· ·WHITE & CASE LLP
`· · ·BY:· SILVIA MEDINA, ESQUIRE
`·8· ·BY:· ROBERT E. COUNIHAN, ESQUIRE
`· · ·1155 Avenue of the Americas
`·9· ·New York, New York 10036
`· · ·212.819.8255
`10· ·silvia.medina@whitecase.com
`· · ·rcounihan@whitecase.com
`11· ·Counsel for the Defendant
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 2
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 3
`
`·1· · · · · · · · · · ·I· N· D· E X
`
`·2· ·Testimony of:· LEONARD J. CHYALL, Ph.D.
`
`·3
`· · ·By Mr. Holloway................5
`·4· · · · · · · · · · · · -· ·-· ·-
`
`·5· · · · · · · · · E· X· H· I· B· I· T S
`
`·6· · · · · · · · · · · · -· ·-· ·-
`
`·7· ·EXHIBIT NUMBER· · DESCRIPTION· · · · · · · · · ·PAGE
`
`·8· ·Exhibit 1· · · Expert Report of Leonard
`· · · · · · · · · · J. Chyall, Ph.D. Regarding
`·9· · · · · · · · · Validity
`
`10· ·Exhibit 1A· · ·Exhibit A
`
`11
`· · ·Exhibit 2· · · Rebuttal Expert Report of
`12· · · · · · · · · Leonard J. Chyall, Ph.D.
`· · · · · · · · · · Regarding Validity
`13
`· · ·Exhibit 2A· · ·Exhibit B
`14
`· · ·Exhibit 3· · · Opening Expert Report of
`15· · · · · · · · · David R. Janero, Ph.D.
`
`16· ·Exhibit 4· · · United States Patent No.:
`· · · · · · · · · · US 6,858,650 B1
`17
`· · ·Exhibit 5· · · Document entitled
`18· · · · · · · · · Schwarz Pharma AG
`
`19· ·Exhibit 6· · · E-mail to Arth from Meese
`· · · · · · · · · · dated 8/3/99
`20
`· · ·Exhibit 7· · · Document entitled
`21· · · · · · · · · Analytical Summary
`· · · · · · · · · · SPM 909 (007)
`22
`· · ·Exhibit 8· · · Gould paper
`23
`· · ·Exhibit 9· · · Document entitled
`24· · · · · · · · · Salt selection for basic drugs
`
`25
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 3
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 4
`
`·1· ·EXHIBIT NUMBER· · DESCRIPTION· · · · · · · · · ·PAGE
`
`·2· ·Exhibit 10· · ·Document entitled
`· · · · · · · · · · International Application
`·3· · · · · · · · · Published Under the Patent
`· · · · · · · · · · Cooperation Treaty (PCT)
`·4
`
`·5
`
`·6
`
`·7
`
`·8
`
`·9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 4
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 5
`
`·1· · · · · · · · ·LEONARD CHYALL, Ph.D., after having
`
`·2· · · · been first duly sworn, was examined and
`
`·3· · · · testified as follows:
`
`·4· ·EXAMINATION BY MR. HOLLOWAY:
`
`·5· · · · Q· · · · Dr. Chyall, could you please state
`
`·6· ·your name for the record?
`
`·7· · · · A· · · · Leonard J. Chyall.
`
`·8· · · · Q· · · · And you have been retained as an
`
`·9· ·expert witness in this case; is that correct?
`
`10· · · · A· · · · Yes, I have.
`
`11· · · · Q· · · · Were you retained by White & Case or
`
`12· ·by UCB Pharma and/or Pfizer?
`
`13· · · · A· · · · I don't remember from the engagement
`
`14· ·letter.
`
`15· · · · Q· · · · And you provided two reports in this
`
`16· ·case, correct?
`
`17· · · · A· · · · Yes, sir.
`
`18· · · · Q· · · · And when I say "this case," I'm
`
`19· ·talking about the case that Pfizer and UCB Pharma
`
`20· ·have brought against Mylan, as opposed to the case
`
`21· ·where you previously testified before Judge Sleet
`
`22· ·concerning fesoterodine; is that fair?
`
`23· · · · A· · · · Yes.
`
`24· · · · Q· · · · If at any point in time before I hand
`
`25· ·you your reports if you'd like to see them, just let
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 5
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 6
`
`·1· ·me know and I will hand them to you, okay?
`
`·2· · · · A· · · · Okay.
`
`·3· · · · Q· · · · About how many times -- and I don't
`
`·4· ·mean to exclude -- let me just start over.
`
`·5· · · · · · · · ·How many times including times where
`
`·6· ·you have testified have you been retained as an
`
`·7· ·expert in the pharmaceutical field?
`
`·8· · · · A· · · · With respect to -- I have to think a
`
`·9· ·little carefully because I just don't know offhand.
`
`10· ·I personally have worked on about 35 projects in the
`
`11· ·capacity of an independent consultant.· Nearly all
`
`12· ·of them relate to pharmaceuticals.
`
`13· · · · Q· · · · And these projects, are you talking
`
`14· ·about everything you do in your profession, or are
`
`15· ·you limiting it -- are you limiting that to
`
`16· ·consulting for attorneys or companies in the patent
`
`17· ·context?
`
`18· · · · A· · · · The 35 would be everything.· It would
`
`19· ·be a smaller number for providing consulting to
`
`20· ·attorneys.· But the bulk of the work that I'm doing
`
`21· ·now is assisting attorneys understand scientific
`
`22· ·matters.· With respect to expert witnessing, I
`
`23· ·average about two projects a year, and I probably
`
`24· ·have the best numbers there because I know from my
`
`25· ·CV where I'm required to list expert testimony.· In
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 6
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 7
`
`·1· ·any given moments my CV usually contains eight
`
`·2· ·matters, so it works out to be about two a year.
`
`·3· · · · Q· · · · And do -- I'm looking for a proportion
`
`·4· ·of your time spent in a given year.· What's the
`
`·5· ·proportion of time spent where you are working with
`
`·6· ·attorneys providing technical consulting as you just
`
`·7· ·explained versus the other work that you're doing in
`
`·8· ·your independent consultancy?
`
`·9· · · · A· · · · It's going to vary depending on the
`
`10· ·year.· At present more than half.
`
`11· · · · Q· · · · And about how long has that been the
`
`12· ·case?
`
`13· · · · A· · · · For the past two or three years, I
`
`14· ·believe.
`
`15· · · · Q· · · · What kind of work do you do when
`
`16· ·you're not providing assistance to attorneys on
`
`17· ·legal matters?
`
`18· · · · A· · · · One example that I worked on involved
`
`19· ·helping a company troubleshoot an issue with their
`
`20· ·manufacturing process.
`
`21· · · · Q· · · · And how did you go about helping -- if
`
`22· ·the details you can't share with me because they're
`
`23· ·confidential or whatever, I don't necessarily want
`
`24· ·those, or if they're covered by a privilege that's
`
`25· ·beyond what your current counsel has with you.· I'm
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 7
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 8
`
`·1· ·just trying to get a understanding of the nature of
`
`·2· ·the type of work that you would do.
`
`·3· · · · A· · · · That's understood.· That's fair.
`
`·4· ·There was some product that was not passing their
`
`·5· ·quality specification.· And the product had to be --
`
`·6· ·could not be sold because of that.· And I was tasked
`
`·7· ·with trying to understand why that was so from a
`
`·8· ·chemistry perspective.
`
`·9· · · · Q· · · · Was this a pharmaceutical product?
`
`10· · · · A· · · · It was a personal care product.
`
`11· · · · Q· · · · Personal care product.· So was it
`
`12· ·something that had to go through any type of FDA
`
`13· ·clearance in order to be sold or marketed?
`
`14· · · · A· · · · I believe so.· I wasn't involved in
`
`15· ·that aspect of it, but I believe that product would
`
`16· ·fall under the umbrella of the FDA.
`
`17· · · · Q· · · · Was the product already being sold and
`
`18· ·then you were helping figure out why it was failing
`
`19· ·in the market, or were they trying to get the
`
`20· ·product to market and having difficulties doing
`
`21· ·that?
`
`22· · · · A· · · · It was a commercial product that could
`
`23· ·not be released because it had failed an internal
`
`24· ·test.
`
`25· · · · Q· · · · Okay.· And what was the nature of the
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 8
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 9
`
`·1· ·science that you worked on in assisting that
`
`·2· ·company?
`
`·3· · · · A· · · · Related to organic chemistry.· It was
`
`·4· ·an aspect of organic chemistry, which is my area of
`
`·5· ·expertise.
`
`·6· · · · Q· · · · And was it part of the manufacturing
`
`·7· ·process, the chemistry, or would it have to do with
`
`·8· ·the specific organic molecules in the product that
`
`·9· ·were degrading?
`
`10· · · · A· · · · I believe that it was due to both.
`
`11· · · · Q· · · · In the cases that you have consulted
`
`12· ·with -- in the projects where you have consulted
`
`13· ·with attorneys, how many of those have related to
`
`14· ·the chemistry involving the salts of a
`
`15· ·pharmaceutical compound?
`
`16· · · · A· · · · Offhand roughly half a dozen, maybe
`
`17· ·more.
`
`18· · · · Q· · · · Before you started in your
`
`19· ·consultancy, did you have any specific experience in
`
`20· ·salt chemistry or organic salt chemistry?
`
`21· · · · A· · · · Yes.
`
`22· · · · Q· · · · And could you describe the nature of
`
`23· ·that previous experience?
`
`24· · · · A· · · · From the year 2000 until I founded my
`
`25· ·own company in 2011, I worked for an expert contract
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 9
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 10
`
`·1· ·research lab called SSCI.· That lab was in the
`
`·2· ·business of conducting salt screens and salt
`
`·3· ·selection work for the pharmaceutical industry.· So
`
`·4· ·in my capacity as an employee of that company, I did
`
`·5· ·a lot of salt screening.
`
`·6· · · · Q· · · · And so you were there 11 years?
`
`·7· · · · A· · · · I believe so, yes.
`
`·8· · · · Q· · · · When you started at -- was it SSCI?
`
`·9· · · · A· · · · Yes.
`
`10· · · · Q· · · · When you started at SSCI, what was
`
`11· ·your job title?
`
`12· · · · A· · · · Research chemist, I believe, something
`
`13· ·like that.
`
`14· · · · Q· · · · What did you do on a daily basis?
`
`15· · · · A· · · · It definitely varied.· Because of the
`
`16· ·nature of contract research, I had a variety of
`
`17· ·different responsibilities.· Some of those
`
`18· ·responsibilities included working on protocol
`
`19· ·projects on behalf of clients.· I was also involved
`
`20· ·in some research and development for the company.
`
`21· ·So I didn't really have a routine day there.
`
`22· · · · Q· · · · You have talked -- I think you have
`
`23· ·said twice now that SSCI was in the contract
`
`24· ·chemistry work.· What do you mean by that?
`
`25· · · · A· · · · SSCI would be hired by other companies
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 10
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 11
`
`·1· ·to carry out one aspect of the drug development
`
`·2· ·process for that company.· SSCI had a great deal of
`
`·3· ·expertise in pharmaceutical solids.· So that type of
`
`·4· ·research would be contracted to SSCI to conduct.
`
`·5· · · · Q· · · · So -- and part of that work I
`
`·6· ·understand would be helping the company that might
`
`·7· ·have an active pharmaceutical ingredient to find a
`
`·8· ·viable salt so that it could be turned into a
`
`·9· ·formulation; is that correct?
`
`10· · · · A· · · · That was one aspect of our service
`
`11· ·offerings, yes.
`
`12· · · · Q· · · · In your 11 years there did you have
`
`13· ·experience in that specific aspect of it?
`
`14· · · · A· · · · Absolutely, yes.
`
`15· · · · Q· · · · So describe the typical case for me
`
`16· ·where a pharmaceutical company that's not SSCI comes
`
`17· ·to SSCI and says, We need help.
`
`18· · · · A· · · · The business model of SSCI was not
`
`19· ·cookie cutter in that we had a typical service
`
`20· ·offering.· So the research protocols were highly
`
`21· ·tailored towards particular clients, and the
`
`22· ·particular molecule, and the specific needs that
`
`23· ·that client needs be addressed.
`
`24· · · · Q· · · · So when a third-party pharmaceutical
`
`25· ·company first contacts SSCI, it's not, We need help
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 11
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 12
`
`·1· ·finding a salt?· Is it more specific than that when
`
`·2· ·they first contact you?
`
`·3· · · · A· · · · Again, it is going to depend.· There
`
`·4· ·could be very specific tasks that the pharmaceutical
`
`·5· ·company might ask us to do, but some projects were
`
`·6· ·extraordinarily general in that -- one example would
`
`·7· ·be we have -- we have a very promising, active
`
`·8· ·moiety.· Moiety is a term of the art that means a
`
`·9· ·group, active group.· We need to render this active
`
`10· ·group into a form that's going to be
`
`11· ·commercializable.· And we don't know what it is yet.
`
`12· ·Can you help us figure that out?
`
`13· · · · · · · · ·So salt selection might be on the
`
`14· ·list.· Crystal form screening might be on the list.
`
`15· ·So those projects tend to be more general than, say,
`
`16· ·a project that was highly focused on one particular
`
`17· ·thing such as I have an amorphous compound and I
`
`18· ·need to crystalize it.· SSCI, would you please help
`
`19· ·me crystalize it?· That would be another example of
`
`20· ·a project.
`
`21· · · · Q· · · · You said crystal form analysis.· Is
`
`22· ·that looking for different polymorphs of a crystal?
`
`23· · · · A· · · · No.· That project that I -- that
`
`24· ·hypothetical project I just mentioned would have
`
`25· ·involved trying to render something that wasn't
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 12
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 13
`
`·1· ·crystalline into a crystalline form.
`
`·2· · · · Q· · · · So is that the same thing as when you
`
`·3· ·just described having an amorphous compound and
`
`·4· ·wanting it made crystalline?
`
`·5· · · · A· · · · Correct.· That's one type of research
`
`·6· ·project that I worked on.· And you mentioned
`
`·7· ·polymorph screens.· That's another type of research
`
`·8· ·project that I'm familiar with.
`
`·9· · · · Q· · · · But the polymorph screens, that wasn't
`
`10· ·what you were referring to when you said, they might
`
`11· ·want us to do some crystalline form analysis?
`
`12· · · · A· · · · Correct.
`
`13· · · · Q· · · · In your own consultancy that you just
`
`14· ·started, do you do any salt screen or salt selection
`
`15· ·work?
`
`16· · · · A· · · · Yes.
`
`17· · · · Q· · · · And about how many of those projects
`
`18· ·has your firm undertaken in the last five years?
`
`19· · · · A· · · · Two, one or two.
`
`20· · · · Q· · · · One or two, okay.· And who are they
`
`21· ·for?
`
`22· · · · A· · · · I'm not at liberty to say, but in
`
`23· ·general they are for pharmaceutical companies.
`
`24· · · · Q· · · · Were either one of them for UCB?
`
`25· · · · · · · · ·MS. MEDINA:· Objection.
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 13
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 14
`
`·1· · · · · · · · ·THE WITNESS:· I'm not at liberty to
`
`·2· · · · say.
`
`·3· ·BY MR. HOLLOWAY:
`
`·4· · · · Q· · · · So if they were for UCB or Pfizer, I
`
`·5· ·would get to know that?
`
`·6· · · · · · · · ·MR. COUNIHAN:· Are you talking about
`
`·7· · · · privileged information or are you talking about
`
`·8· · · · research?
`
`·9· · · · · · · · ·MR. HOLLOWAY:· I will tell you that
`
`10· · · · this is as far as the question goes.· I'm not
`
`11· · · · going to ask any details about what it is or
`
`12· · · · anything like that.· I would just like to know
`
`13· · · · if either of the salt screening projects he's
`
`14· · · · done at his own company have been for UCB or
`
`15· · · · Pfizer.
`
`16· · · · · · · · ·MR. COUNIHAN:· Yes.· So I'll just
`
`17· · · · instruct the witness that he can answer yes or
`
`18· · · · no as long as it doesn't reveal any privileged
`
`19· · · · information.
`
`20· · · · · · · · ·I also -- just out of an abundance of
`
`21· · · · caution, I'm not sure whether stuff that
`
`22· · · · Dr. Chyall has talked about is confidential,
`
`23· · · · but I do want to mark this transcript
`
`24· · · · confidential at this point, even though there
`
`25· · · · are some automatic provisions in the protective
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 14
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 15
`
`·1· · · · order you're well aware of regarding
`
`·2· · · · confidentiality.
`
`·3· · · · · · · · ·So with that instruction, Dr. Chyall,
`
`·4· · · · you can answer yes or no.
`
`·5· ·BY MR. HOLLOWAY:
`
`·6· · · · Q· · · · So I'll go back to it.· Do you
`
`·7· ·understand what he's saying you to?
`
`·8· · · · A· · · · Yes.
`
`·9· · · ·
`
`19· · · · Q· · · · So I'm going to leave that, so don't
`
`20· ·mistakenly think that my questions have to do with
`
`21· ·that project, okay?
`
`22· · · · A· · · · Okay.
`
`23· · · · Q· · · · So actually I'll make it even easier.
`
`24· ·Let's go back to SSCI.
`
`25· · · · A· · · · Okay.
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 15
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 16
`
`·1· · · · Q· · · · Did you ever have an experience at
`
`·2· ·SSCI where a pharmaceutical company came in and
`
`·3· ·said, we have an active pharmaceutical ingredient;
`
`·4· ·we'd like you to find a salt for it?
`
`·5· · · · A· · · · Yes.
`
`·6· · · · Q· · · · And could you describe for me how that
`
`·7· ·process would have worked in your time at SSCI?
`
`·8· · · · A· · · · The client would have worked with a
`
`·9· ·director of the company to understand specific
`
`10· ·issues, in particular the reasons why a salt screen
`
`11· ·was being requested.· And based on our expertise if
`
`12· ·that basis was reasonable scientifically, then we
`
`13· ·would design protocol work that was tailored to that
`
`14· ·particular drug.
`
`15· · · · Q· · · · When you say to determine if there was
`
`16· ·a basis scientifically for going down the salt
`
`17· ·screen process, what would be an example of a
`
`18· ·nonscientifically sound basis for going through salt
`
`19· ·screening?
`
`20· · · · A· · · · If the client had generated -- as one
`
`21· ·example, if the client had generated a solid that
`
`22· ·was amorphous and they felt like they needed the
`
`23· ·salt because the amorphous solid wasn't crystalline,
`
`24· ·we -- SSCI would say that perhaps the issue is just
`
`25· ·that you haven't identified the right conditions to
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 16
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 17
`
`·1· ·render this amorphous solid into a crystalline
`
`·2· ·solid.· So perhaps it would make sense to make sure
`
`·3· ·that you're not excluding the drug in its present
`
`·4· ·form just based on the fact that you cannot render
`
`·5· ·it crystalline.· Perhaps we should try that first.
`
`·6· · · · Q· · · · And so assuming that the director at
`
`·7· ·SSCI found that there was a scientifically valid
`
`·8· ·reason for proceeding down salt screening, how would
`
`·9· ·that have played out internally at SSCI going
`
`10· ·forward?
`
`11· · · · A· · · · We would have asked the company to
`
`12· ·provide us with as much information as possible
`
`13· ·concerning the scientific characterization that had
`
`14· ·been done on that particular drug.· We would be
`
`15· ·interested in a whole variety of properties of the
`
`16· ·drug substance.
`
`17· · · · · · · · ·And then based on the structure and
`
`18· ·some other issues that would have been uncovered and
`
`19· ·a review of that body of work, directors of the
`
`20· ·company would have designed a protocol that laid out
`
`21· ·a proposed research program to identify salt forms.
`
`22· ·And costs and timing and things like that would have
`
`23· ·been included in the protocol.
`
`24· · · · Q· · · · What are some of the properties of the
`
`25· ·pharmaceutical compound that would have been brought
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 17
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 18
`
`·1· ·to SSCI, are the properties that you were
`
`·2· ·referencing in the body of work that would need to
`
`·3· ·be reviewed?
`
`·4· · · · A· · · · Well, certainly the structure is
`
`·5· ·important.
`
`·6· · · · Q· · · · When you say the structure, you mean
`
`·7· ·the chemical structure of the molecule?
`
`·8· · · · A· · · · Correct, the manner in which the atoms
`
`·9· ·are bonded together.· So the solubility of the drug
`
`10· ·substance would have been of interest.· We would
`
`11· ·have been interested in the types of functional
`
`12· ·groups that are present in the molecule.· And I
`
`13· ·guess that's part of the structure.· But we would
`
`14· ·have had an eye toward the properties with respect
`
`15· ·to acid-based chemistry.
`
`16· · · · Q· · · · By that you mean like PKA or PKB
`
`17· ·values?
`
`18· · · · A· · · · Yes.· And any kind of characterization
`
`19· ·of the material is the starting point, a liquid or a
`
`20· ·solid.· That would have been important.
`
`21· · · · · · · · ·Also, any kind of information from the
`
`22· ·sponsor of this work with respect to pharmacokinetic
`
`23· ·issues, will this be an oral tablet, will it be
`
`24· ·administered transdermally, those types of things.
`
`25· ·If there's any information that those involved in
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 18
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 19
`
`·1· ·the pharmacokinetic aspects of the drug could
`
`·2· ·provide to us that would guide us in selecting
`
`·3· ·starting points, then we would do that.
`
`·4· · · · Q· · · · In your experience at SSCI, was it
`
`·5· ·more common for a pharmaceutical company to
`
`·6· ·investigate oral dosage forms or transdermal dosage
`
`·7· ·forms?
`
`·8· · · · A· · · · We did a lot of work for different
`
`·9· ·delivery mechanisms other than oral.· Certainly we
`
`10· ·did a lot of work for all dosage forms, but a lot of
`
`11· ·the work we did was indeed directed toward some
`
`12· ·rather scientifically interesting delivery devices.
`
`13· ·We did work on pharmaceutical stents, lozenges, as
`
`14· ·well as transdermal work.· So I have seen a lot of
`
`15· ·different types of drugs.
`
`16· · · · Q· · · · In the salt screens that you worked on
`
`17· ·at SSCI, what was the proportion of oral dosage
`
`18· ·forms to the rest?
`
`19· · · · A· · · · Certainly more than half.· I'm not
`
`20· ·sure exactly.
`
`21· · · · Q· · · · You mentioned characterization of the
`
`22· ·material, is it a liquid or a solid.· You're
`
`23· ·referring there to the starting material that's the
`
`24· ·active pharmaceutical moiety that the pharmaceutical
`
`25· ·company would have brought to you?
`
`
`
`www.huseby.comwww.huseby.com
`Huseby, Inc.· Regional CentersHuseby, Inc.· Regional Centers
`
`800-333-2082800-333-2082
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San FranciscoCharlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`YVer1f
`
`PROTECTIVE ORDER MATERIAL
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1075A - Page 19
`
`
`
`
`
`ConfidentialConfidential
`
`
`PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.PFIZER INC., ET AL. vs. MYLAN PHARMACEUTICALS, INC.
`
`Leonard J. Chyall on 08/23/2016Leonard J. Chyall on 08/23/2016
`
`Page 20
`
`·1· · · · A· · · · Correct.
`
`·2· · · · Q· · · · If it was a solid, what would be some
`
`·3· ·of the characteristics that SSCI would be interested
`
`·4· ·in at the beginning of the salt screening phase?
`
`·5· · · · A· · · · Certainly the solubility of the solid.
`
`·6· · · · Q· · · · Is that it?
`
`·7· · · · A· · · · Any kind of stability issues, whether
`
`·8· ·it was light sensitive or not.
`
`·9· · · · Q· · · · I'm assuming included in this would be
`
`10· ·melting point information?
`
`11· · · · A· · · · Yes.
`
`12· · · · Q· · · · What about DSC i